Ligand Pharmaceuticals (LGND) EBIT (2010 - 2026)

Ligand Pharmaceuticals has disclosed EBIT across 17 years of filings, most recently posting $17.4 million for Q1 2026.

• EBIT for Q1 2026 came in at $17.4 million, up 147.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $94.6 million (up 253.03% YoY), and the FY2025 annual result was $41.0 million, up 281.38% from the prior year.
• EBIT came in at $17.4 million for Q1 2026 at Ligand Pharmaceuticals, up from $13.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $54.9 million in Q3 2025 to a low of -$36.2 million in Q1 2025.
• The 5-year median for EBIT is $3.1 million (2023), against an average of $3.0 million.
• Peak annual rise in EBIT reached 1647.73% in 2025, while the deepest fall reached 1312.05% in 2025.
• Ligand Pharmaceuticals' EBIT stood at -$20.1 million in 2022, then jumped by 83.29% to -$3.4 million in 2023, then plunged by 186.99% to -$9.6 million in 2024, then surged by 243.64% to $13.8 million in 2025, then rose by 25.46% to $17.4 million in 2026.
• The last three EBIT figures came in at $17.4 million (Q1 2026), $13.8 million (Q4 2025), and $54.9 million (Q3 2025), per Business Quant data.